Skip to content

Trial Summary

This is a non-interventional/observational cohort of NSCLC unresectable stage III patients treated with durvalumab. The study will be carried out as a retrospective review of established medical records for a subset of unresectable stage III patients treated with durvalumab.

Acronym:

Pacific-R

ACTRN/NCT /ethics:

NCT03798535

Scientific title:

First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy

Sponsor / Cooperative group:

AstraZaneca

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeTreatment
PhaseAll phases
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2018-12-18
Anticipated End Date2023-12-01

Participating Hospitals

HospitalCalvary Central Districts Hospital
Clinical Trial CoordinatorJulie Rowe
Emailjulie.rowe@calvarycare.org.au
Phone08 8239 9536
Principal Investigator08 8239 9536
Recruitment StatusRecruitment on Hold
HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorDr Shawgi Sukumaran
Recruitment StatusNot Yet Recruiting